Page 118 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Cholesteatoma enrichment pathways for drug repurposing

18. Jiang H, Si Y, Li Z, et al. TREM-2 promotes acquired 25. Dambergs K, Sumeraga G, Pilmane M. Morphopathogenesis
cholesteatoma-induced bone destruction by modulating of adult acquired cholesteatoma. Medicina (Kaunas).
TLR4 signaling pathway and osteoclasts activation. Sci 2023;59(2):306.
Rep. 2016;6:38761.
doi: 10.3390/medicina59020306
doi: 10.1038/srep38761
26. Imai R, Sato T, Iwamoto Y, et al. Osteoclasts modulate bone
19. Laeeq S, Faust R. Modeling the cholesteatoma erosion in cholesteatoma via RANKL signaling. J Assoc Res
microenvironment: Coculture of HaCaT keratinocytes Otolaryngol. 2019;20(5):449-459.
with WS1 fibroblasts induces MMP-2 activation, invasive doi: 10.1007/s10162-019-00727-1
phenotype, and proteolysis of the extracellular matrix.
Laryngoscope. 2007;117(2):313-318. 27. Heo KW, Noh MH, Hur DY, Hong TU, Park SY, Kim WJ.
Bone destruction in chronic otitis media is not mediated by
doi: 10.1097/01.mlg.0000251164.26405.1a
the RANKL pathway or estrogen receptor-alpha. Sci Prog.
20. Lei Y, An J, Ren Q, Wang M, Gao M. Expression of MMP-14 2023;106(3):368504231199204.
and its role in bone destruction in middle ear cholesteatoma:
A prospective observational study. Medicine (Baltimore). doi: 10.1177/00368504231199204
2023;102(44):e35538. 28. Liu W, Ren H, Ren J, et al. The role of EGFR/PI3K/Akt/
cyclinD1 signaling pathway in acquired middle ear
doi: 10.1097/MD.0000000000035538
cholesteatoma. Mediators Inflamm. 2013;2013:651207.
21. Kan T, Ueda H, Takahara T, et al. Association of matrix
metalloproteinase-2 mRNA expression with subtypes of doi: 10.1155/2013/651207
pediatric cholesteatoma. Biomed Res Int. 2021;2021:6644897. 29. Huisman MA, De Heer E, Grote JJ. Survival signaling and
terminal differentiation in cholesteatoma epithelium. Acta
doi: 10.1155/2021/6644897
Otolaryngol. 2007;127(4):424-429.
22. Erbek S, Erinanc H, Hizal E, Ozluoglu LN. Expression of
disintegrin and metalloproteinase family proteins 10, 12 and doi: 10.1080/00016480600868430
17 in cholesteatoma. J Laryngol Otol. 2013;127(2):153-158. 30. Yune TY, Byun JY. Expression of PTEN and phosphorylated
Akt in human cholesteatoma epithelium. Acta Otolaryngol.
doi: 10.1017/S0022215112003106
2009;129(5):501-506.
23. Juhász A, Sziklai I, Rákosy Z, Ecsedi S, Ádány R, Balázs M.
Elevated level of tenascin and matrix metalloproteinase doi: 10.1080/00016480802258802
9 correlates with the bone destruction capacity of 31. Schürmann M, Oppel F, Shao S, et al. Chronic inflammation
cholesteatomas. Otol Neurotol. 2009;30(4):559-565. of middle ear cholesteatoma promotes its recurrence via a
paracrine mechanism. Cell Commun Signal. 2021;19(1):25.
doi: 10.1097/MAO.0b013e31819fe6ed
doi: 10.1186/s12964-020-00690-y
24. Yetiser S, Satar B, Aydin N. Expression of epidermal growth
factor, tumor necrosis factor-alpha, and interleukin-1alpha 32. Chao J, Dewyer N, McKenna MJ. Spontaneous resolution
in chronic otitis media with or without cholesteatoma. Otol of cholesteatoma in a patient on long-term infliximab. Ann
Neurotol. 2002;23(5):647-652. Otol Rhinol Laryngol. 2019;128(4):365-368.
doi: 10.1097/00129492-200209000-00007 doi: 10.1177/0003489418823790

Volume 8 Issue 3 (2025) 112 doi: 10.36922/itps.2571